Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CCND2
REST API REST API
Homo sapiens
CCND2 is differentially expressed in 377 experiments: 167 organism parts: liver, adrenal gland, ... (165 more);, 266 disease states: normal, control, ... (264 more);, 149 cell types 509 cell lines 48 compound treatments and 80 other conditions.
Orthologs CCND2_BOVIN (Bos taurus)   ccnd2b (Danio rerio)   Ccnd2 (Mus musculus)   CCND2_RAT (Rattus norvegicus)   F6S8K9_CIOIN (Ciona intestinalis)   CCND2_CHICK (Gallus gallus)   ccnd2a (Danio rerio)   CycD (Drosophila melanogaster)   ccnd2 (Xenopus laevis)   CCND2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, cell division, protein binding, cytoplasm, positive regulation of cell proliferation, membrane, regulation of cyclin-dependent protein kinase activity, spermatogenesis, response to cAMP, regulation of neuron differentiation, regulation of cell cycle, protein kinase binding, nucleus, chromatin, response to ethanol, nucleolus, nuclear membrane, cellular response to insulin stimulus, response to testosterone stimulus, positive regulation of epithelial cell proliferation, ovarian follicle development, response to peptide hormone stimulus, response to estradiol stimulus, positive regulation of cyclin-dependent protein kinase activity, liver development, cyclin-dependent protein kinase holoenzyme complex, positive regulation of protein phosphorylation, response to organic cyclic compound
InterPro Term Cyclin-like, Cyclin_N, Cyclin_C, Cyclin_A/B/D/E
UniProt Accession P30279
Search EB-eye ENSG00000118971
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, ... (34 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
SW480
3
E-MEXP-1014, E-GEOD-2509, E-GEOD-18005
MCF-10A
2
E-TABM-420, E-GEOD-14990
MOLT4
2
E-MTAB-62, E-MTAB-37
SNU1
2
E-GEOD-15460, E-MTAB-37
T84
2
E-GEOD-1474, E-MTAB-37
503 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (65 experiments)

Factor Value U/D Experiments
stromal cell
1
4
E-MEXP-1327, E-MEXP-2034, E-GEOD-3998, E-GEOD-1460, E-GEOD-10797 ... (5 experiments)
mesenchymal stem cell
3
E-GEOD-2248, E-MEXP-466, E-GEOD-9894
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
dendritic cell
2
E-GEOD-360, E-GEOD-3982
1
2
E-TABM-145, E-TABM-130
143 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (80 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
4
E-MTAB-62, E-GEOD-96, E-MEXP-2034, E-TABM-26, E-MEXP-1327 ... (5 experiments)
control
1
4
E-GEOD-21912, E-GEOD-20295, E-GEOD-16363, E-GEOD-8121, E-GEOD-20168 ... (5 experiments)
acute promyelocytic leukemia
3
E-MTAB-62, E-GEOD-1729, E-GEOD-995
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514
melanoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-7307
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
260 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, ... (30 experiments)

Factor Value U/D Experiments
none
3
6
E-MEXP-1601, E-GEOD-2803, E-MEXP-1958, E-GEOD-2649, E-MEXP-1269, ... (9 experiments)
interleukin-22 (Homo sapiens)
1
E-GEOD-7216
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
endotoxin
1
E-GEOD-3026
saline
1
E-GEOD-3026
42 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
137.36
1
1
E-TABM-325


Age at diagnosis
studied in E-GEOD-21653

Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-19246, E-GEOD-21374, E-GEOD-21589, ... (17 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-2509, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-MTAB-108, ... (8 experiments)

Genotype
studied in E-TABM-763, E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-22278, E-TABM-440, E-GEOD-837, E-MEXP-1273, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276, E-GEOD-20194, E-GEOD-16716, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-GEOD-2466, E-MEXP-2069, ... (45 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-5824, E-GEOD-1657, ... (11 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-2018, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-4922

Processing time: 0.356 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM